Post by babaoriley on Apr 2, 2014 9:38:02 GMT -5
I hope he says something like, "we thrilled with the results of the hearing and all the hard work our team put in to help make it successful, but by far, our favorite part of the hearing was the testimony from the public... it actually brought tears to my eyes" (okay, last part perhaps over the top, but it actually might have!).
And then go on to describe the public testimony - let's get a wide audience to hear just what actual patients, and ADA (unmet need) and Endocrinologists who are in the front lines said. Almost no one saw the hearing yesterday, but to me, that public testimony, a hundred times more than anything else said in that hearing, is the evidence of the magnitude of the potential of this product. Mentioning the size of the market in front of millions of investors doesn't hurt either. We recognize the enormity of yesterdays hearing, few others do, especially the retail investor. I hope Matt can paint a vivid picture of the highlight of the hearing.
Oh, and hopefully, he can honestly say that (serious) negotiations continue for a partner.
This is a golden opportunity for Matt and MNKD, now that attention has been drawn to the stock. I hope he doesn't let himself get bogged down with questions about risks, concerns of the panel, concerns of the FDA, running out of money, and the need for further trials, etc. That could be disastrous, or at least a blown opportunity.
And then go on to describe the public testimony - let's get a wide audience to hear just what actual patients, and ADA (unmet need) and Endocrinologists who are in the front lines said. Almost no one saw the hearing yesterday, but to me, that public testimony, a hundred times more than anything else said in that hearing, is the evidence of the magnitude of the potential of this product. Mentioning the size of the market in front of millions of investors doesn't hurt either. We recognize the enormity of yesterdays hearing, few others do, especially the retail investor. I hope Matt can paint a vivid picture of the highlight of the hearing.
Oh, and hopefully, he can honestly say that (serious) negotiations continue for a partner.
This is a golden opportunity for Matt and MNKD, now that attention has been drawn to the stock. I hope he doesn't let himself get bogged down with questions about risks, concerns of the panel, concerns of the FDA, running out of money, and the need for further trials, etc. That could be disastrous, or at least a blown opportunity.
